Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Clesrovimab

Catalog #:   DVV02808 Specific References (13) DATASHEET
Host species: Human
Isotype: IgG1-kappa
Applications: Research Grade Biosimilar
Expression system: Mammalian Cells
Overview

Catalog No.

DVV02808

Expression system

Mammalian Cells

Species reactivity

RSV (respiratory syncytial virus)

Host species

Human

Isotype

IgG1-kappa

Clonality

Monoclonal

Target

F, Fusion glycoprotein F0, Fusion glycoprotein F2, p27, Intervening segment, Pep27, Peptide 27, Fusion glycoprotein F1

Concentration

2 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P03420

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

MK 1654, MK-1654, MK1654, CAS: 2429913-18-6

Clone ID

Clesrovimab

Data Image
  • Bioactivity
    Detects Human respiratory syncytial virus F/Fusion glycoprotein F0 in indirect ELISAs.
References

Supporting Pediatric RSV Clinical Trials Through Close Epidemiological Surveillance During the SARS-CoV-2 Pandemic., PMID:40312764

Human iPS cell-derived respiratory organoids as a model for respiratory syncytial virus infection., PMID:40262853

Efficacy of monoclonal antibodies and maternal vaccination for prophylaxis of respiratory syncytial virus disease., PMID:40240559

Anti-Idiotypic Antibody as a Booster Vaccine Against Respiratory Syncytial Virus., PMID:39852814

The recent landscape of RSV vaccine research., PMID:39802673

A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants., PMID:39601265

Development of High-Titer Antidrug Antibodies in a Phase 1b/2a Infant Clesrovimab Trial Are Associated With RSV Exposure Beyond Day 150., PMID:39590882

Mind the (preterm) gap: inequality in the UK's current RSV immunisation approach will leave many preterm babies unprotected against RSV this winter., PMID:39379140

Systematic Review of the Efficacy and Safety of RSV-Specific Monoclonal Antibodies and Antivirals in Development., PMID:39209729

Genomic evolution of human respiratory syncytial virus during a decade (2013-2023): bridging the path to monoclonal antibody surveillance., PMID:38588960

[Prevention of respiratory syncytial virus infection in infants. What has been done and where are we today?]., PMID:38329302

Quantification of clesrovimab, an investigational, half-life extended, anti-respiratory syncytial virus protein F human monoclonal antibody in the nasal epithelial lining fluid of healthy adults., PMID:37976891

Development of mRNA vaccines against respiratory syncytial virus (RSV)., PMID:36280532

Datasheet

Document Download

Research Grade Clesrovimab.pdf

 

$ 328
Product specifications
100 μg 328 1 mg 1314

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Clesrovimab [DVV02808]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only